All articles tagged with #debt offering
SpaceX’s SPCX stock fell for a third straight day after a strong IPO run as the company confirmed its first-ever bond offering to refinance a bridge loan; the prospective multi‑billion dollar sale led by major banks could weigh on the stock due to higher borrowing costs, even though shares are about 27% above the IPO price and insiders face upcoming unlock periods.
MicroStrategy, a Bitcoin development company, has priced an upsized $525 million convertible debt offering, with the intention of using the proceeds to purchase more Bitcoin. This move comes as the company aims to add to its existing 205,000 bitcoin stack. The offering, which was originally planned at $500 million, was increased, and purchasers were granted an option to buy up to an additional $78.5 million of the paper, potentially bringing the total proceeds to around $600 million.
SoFi Technologies stock plummeted 11.5% after announcing a $750 million convertible debt offering, leading investors to fear cash constraints and potential dilution of their ownership stakes. However, the move could actually decrease interest costs and increase profits, with plans to redeem high-cost preferred stock and enter into transactions to reduce potential dilution. Despite short-term concerns, the company's long-term profitability outlook and growth potential may present a buying opportunity for investors.
Pfizer plans to raise $31 billion in a debt sale to fund its $43 billion acquisition of Seagen, which is expected to be completed by early 2024. The sale will rank among the largest individual corporate bond sales in US history, marking the largest US corporate debt offering in five years. Despite concerns from investors and uncertainties surrounding the deal, the sale highlights a resurgence in the US corporate bond market after a weak April.
Pfizer plans to raise $31 billion through a debt offering to fund its proposed acquisition of cancer drugmaker Seagen, for what would be its largest takeover since 2009. The debt offering is expected to close on May 19, and the pharma giant's debt offering would be the biggest since CVS Health sold $40 billion of bonds in 2018 to finance its acquisition of health insurer Aetna. The Seagen deal is expected to strengthen Pfizer's portfolio of cancer drugs by bringing a class of antibody-drug conjugates, medicines that are designed to directly kill cancer cells and spare healthy ones.